MAVENIR
13.9.2022 09:01:44 CEST | Business Wire | Press release
Deutsche Telekom and Mavenir announced the successful delivery and deployment of cloud-native 5G Core to Deutsche Telekom in Germany. Deutsche Telekom selected Mavenir as the supplier for software applications to run on its defined hardware and the existing Kubernetes-based platform of its German business, ensuring an open architecture approach. As part of the deployment process, the Converged Packet Core was integrated with Telekom’s existing multi-vendor access network and other system components.
The new Converged Packet Core supports data, voice, and messaging services and network slicing. The initial network slicing use case is focused on live video broadcasting. The deployment has been successfully certified against devices from the major terminal vendors.
The Mavenir solution is based on automated software delivery and network upgrades. This will allow new Converged Packet Core services with all the required network functions to be deployed in minutes by using the automation framework of Deutsche Telekom. It is largely self-updating for the entire lifecycle of each application. The platform can automatically synchronize production environment resources and configuration with changes expressed in code. It is therefore less prone to the human errors that come with manual testing and deployment.
Dr. Abdurazak Mudesir, Group CTO Deutsche Telekom, said: “The deployment of a cloud-native Standalone (SA) core marks a key milestone in the evolution of our 5G architecture. This sets us on a path towards a fully automated network with the reliability, massive scale and flexibility required to deliver innovative 5G SA services to our consumer and enterprise customers.”
Pardeep Kohli, Mavenir’s President and CEO, said, “The Mavenir solution deployed with Deutsche Telekom in Germany, creates the foundation for the future introduction of 5G standalone enabling new applications and services to take advantage of 5G features such as low latency and network slicing.”
Key attributes of Mavenir’s solution include:
- Open Architecture: uses Telekom-defined hardware, a Kubernetes-based platform, and the automation framework of Deutsche Telekom.
- Network slicing support: with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design: a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Telekom’s Containers-as-a-Service (CaaS) that can be run on any public, private or hybrid cloud environment.
- Third-party vendor network function (NF) integration: integrated with multiple third-party vendors, including 4G and 5G access network and subscriber management functions.
- Converged architecture: Supports 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform by Deutsche Telekom.
Mavenir’s Converged Packet Core solution is part of its cloud-native MAVcore portfolio built on an open architecture which offers easy scaling of applications and services, hardware decoupling, agility, portability and resilience.
Supporting Material:
- Case Study YouTube Video: GitOps Based Cloud Native 5GC Lifecycle Management – Based on Mavenir 5GC Implementation in Deutsche Telekom Technik with Das Schiff (T-CaaS @ TDG) Platform - Michal Sewera & Samy Nitsche, Deutsche Telekom
- White Paper: Move as Fast as You Can to the 5GC
A TCO Analysis of the Transition to a Converged 5G Core
- Solution Brief: Mavenir’s Converged Packet Core Solution
About Deutsche Telekom: https://www.telekom.com/companyprofile
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom